Evidence of anti-pyschotic efficacy as an add-on to antipsychotics
Milan, Italy – 5 April 2016 – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN), a biopharmaceutical company
Zambon today announces the availability and reimbursement in Belgium of Xadago® (safinamide) as an add-on to levodopa alone or in combination with other Parkinson’s disease (PD)
Milan, Italy – March 29, 2016 – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN), a research and development company focused on novel CNS and pain therapies, and its partners
Evenamide (NW-3509)
Evidence of anti-psychotic efficacy as an add-on to antipsychotics in ongoing Phase 2 study may suggest an alternative approach to the treatment of
Milano, Italy – 22 March 2016 Newron Pharmaceuticals S.p.A. (“Newron”), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the
Xadago® (safinamide) is already approved in the EU and Switzerland, under review by the U.S. Food and Drug Administration
Drug candidate has potential to assist the more than one
Milan, Italy – March 1, 2016 - Newron Pharmaceuticals S.p.A. (“Newron”), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of
Zambon is announcing today the availability and reimbursement on the Italian market of Xadago® (safinamide) as an add-on to levodopa alone or in combination with other Parkinson’
Milan, Italy, February 29, 2016 - Newron Pharmaceuticals S.p.A. (“Newron”), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of
Spain is the third country in which Xadago® is available for the treatment of adult patients with idiopathic Parkinson’s disease (PD)
Milan – February 22, 2016 – Zambon S.p.A.,
The information on the following pages may be made available in the United States. By clicking on the link below, you agree that you are in the United States.
